Artículos de revistas
Melatonin as a Therapeutic Resource for Inflammatory Visual Diseases
Fecha
2017-08Registro en:
Aranda, Marcos Luis; González Fleitas, María Florencia; Dieguez, Hernan; Iaquinandi, Agustina; Sande Casal, Pablo Horacio; et al.; Melatonin as a Therapeutic Resource for Inflammatory Visual Diseases; Bentham Science Publishers; Current Neuropharmacology; 15; 7; 8-2017; 1-11
1570-159X
CONICET Digital
CONICET
Autor
Aranda, Marcos Luis
González Fleitas, María Florencia
Dieguez, Hernan
Iaquinandi, Agustina
Sande Casal, Pablo Horacio
Dorfman, Damián
Rosenstein, Ruth Estela
Resumen
Background: Uveitis and optic neuritis are prevalent ocular inflammatory diseases, and highly damaging ocular conditions. Both diseases are currently treated with corticosteroids, but they do not have adequate efficacy and are often associated with severe side effects. Thus, uveitis and optic neuritis remain a challenging field to ophthalmologists and a significant public health concern. Objective: This review summarizes findings showing the benefits of a treatment with melatonin in experimental models of these inflammatory ocular diseases. Results: Oxidative and nitrosative damage, tumor necrosis factor, and prostaglandin production have been involved in the pathogeny of uveitis and optic neuritis. Melatonin is an efficient antioxidant and antinitridergic, and has the ability to reduce prostaglandin and tumor necrosis factor levels both in the retina and optic nerve. Moreover, melatonin not only prevents functional and structural consequences of experimental uveitis and optic neuritis, but it is also capable of suppressing the actively ongoing ocular inflammatory response. Conclusions: Since melatonin protects ocular tissues against inflammation, it could be a potentially useful anti-inflammatory therapy in ophthalmology.